A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer’s Disease

Alzheimer’s Disease

1. Nature, incidence, severity, and outcome of AEs, 2. Changes from baseline in vital signs, ECG parameters, Columbia-Suicide Severity Rating Scale (C-SSRS) and safety laboratory findings, 3. Change from baseline in brain amyloid load, as measured by amyloid PET scan

1. Change from baseline in Aβ37, Aβ38, Aβ40 and Aβ42 in CSF and Aβ40 and Aβ42 in plasma, 2. Plasma concentrations of RO7269162 (and its metabolite[s] as appropriate), 3. CSF concentrations of RO7269162 (and its metabolite[s] as appropriate)

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Denmark, France, Germany, Italy, Poland, Spain